TW202400627A - 用於治療眼部疾病之補體因子i之給藥方案 - Google Patents

用於治療眼部疾病之補體因子i之給藥方案 Download PDF

Info

Publication number
TW202400627A
TW202400627A TW112116648A TW112116648A TW202400627A TW 202400627 A TW202400627 A TW 202400627A TW 112116648 A TW112116648 A TW 112116648A TW 112116648 A TW112116648 A TW 112116648A TW 202400627 A TW202400627 A TW 202400627A
Authority
TW
Taiwan
Prior art keywords
cfi
approximately
per eye
weeks
seq
Prior art date
Application number
TW112116648A
Other languages
English (en)
Chinese (zh)
Inventor
古蘭特 E 布勞斯
孟 娜塔莎 拉
湯姆 柯努德森
Original Assignee
美商維泰克斯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商維泰克斯製藥公司 filed Critical 美商維泰克斯製藥公司
Publication of TW202400627A publication Critical patent/TW202400627A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1725—Complement proteins, e.g. anaphylatoxin, C3a or C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
TW112116648A 2022-05-04 2023-05-04 用於治療眼部疾病之補體因子i之給藥方案 TW202400627A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263338392P 2022-05-04 2022-05-04
US63/338,392 2022-05-04

Publications (1)

Publication Number Publication Date
TW202400627A true TW202400627A (zh) 2024-01-01

Family

ID=86760162

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112116648A TW202400627A (zh) 2022-05-04 2023-05-04 用於治療眼部疾病之補體因子i之給藥方案

Country Status (10)

Country Link
US (1) US20250177482A1 (cg-RX-API-DMAC7.html)
EP (1) EP4518881A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515091A (cg-RX-API-DMAC7.html)
KR (1) KR20250008764A (cg-RX-API-DMAC7.html)
CN (1) CN119698286A (cg-RX-API-DMAC7.html)
AU (1) AU2023265150A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251504A1 (cg-RX-API-DMAC7.html)
IL (1) IL316772A (cg-RX-API-DMAC7.html)
TW (1) TW202400627A (cg-RX-API-DMAC7.html)
WO (1) WO2023215840A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117551A1 (en) * 2018-10-23 2020-04-30 Gemini Therapeutics Inc. Compositions and methods for treating age-related macular degeneration and other diseases
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021257480A2 (en) * 2020-06-14 2021-12-23 Catalyst Biosciences, Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
KR20250008764A (ko) 2025-01-15
JP2025515091A (ja) 2025-05-13
AU2023265150A1 (en) 2024-11-14
CA3251504A1 (en) 2023-11-09
CN119698286A (zh) 2025-03-25
WO2023215840A1 (en) 2023-11-09
EP4518881A1 (en) 2025-03-12
IL316772A (en) 2025-01-01
US20250177482A1 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
Duh et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth
US7973009B2 (en) Methods and compositions for the prevention and treatment of anemia
EP1961425B1 (en) Methods and erythropoeitin analogs for the prevention and treatment of anemia
CN100528235C (zh) 红细胞生成素共轭物
US20250136965A1 (en) Complement factor i-related compositions and methods
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
JPH0720431B2 (ja) ミュレル管抑制物質の活性を示すポリペプチドをコードするdna,組換dnaおよび形質転換宿主
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
JP2001000194A (ja) 神経成長因子を真核生物細胞において発現させるための遺伝子ベクター
KR20240000391A (ko) N-말단 및/또는 c-말단이 절단된 가용성 ph20 폴리펩티드 및 이의 용도
CN114401737A (zh) 用于治疗或预防眼科病症的药剂
AU2016301962A9 (en) Heteromers comprising antibody domain fusion proteins
CN118804759A (zh) 补体因子i相关的组合物和方法
TW202602913A (zh) 包含阿柏西普和其變體的組合物以及相關方法和應用
US20250177482A1 (en) Complement factor i dosing regimens for treating ocular diseases
JP2012511309A (ja) Ec−sodのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質
US20040192589A1 (en) Production of high molecular mass lectins
US20220168434A1 (en) Application of transthyretin in entering eye and preparing drop
HK40072504A (en) Agent for use in treatment or prevention of ophthalmic disorders
CN116635528A (zh) 补体因子i相关组合物和方法
JPWO1996028182A1 (ja) Tpoの吸着防止方法および安定なtpo含有組成物